GTS5:CDKN2A-related tumour predisposition syndrome (CDKN2A): Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| Line 27: | Line 27: | ||
==Related Terminology== | ==Related Terminology== | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
|Acceptable | |Acceptable | ||
| | |N/A | ||
|- | |- | ||
|Not Recommended | |Not Recommended | ||
| | |N/A | ||
|} | |} | ||
Acceptable (depending on the tumour spectrum present in the kindred): familial dysplastic naevi/melanoma with germline CDKN2A alteration; familial atypical mole–malignant melanoma syndrome (FAMMM) with germline CDKN2A alteration; susceptibility to cutaneous malignant melanoma type 2 (CMM2); melanoma and neural system tumour syndrome; melanoma-astrocytoma syndrome; melanoma-pancreatic cancer syndrome. | |||
Other: | |||
Not recommended (due to lack of specificity for the underlying causative gene): familial dysplastic naevi/melanoma; familial atypical mole–malignant melanoma syndrome; hereditary melanoma. | |||
==Definition/Description of Disease== | ==Definition/Description of Disease== | ||